Complexo Hospitalario Universitario de Ferrol
Centro de atención
María
Chaparro Sánchez
Publicacións nas que colabora con María Chaparro Sánchez (16)
2023
-
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease
Clinical Gastroenterology and Hepatology, Vol. 21, Núm. 3, pp. 771-788.e10
2022
-
Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)
Journal of Clinical Medicine
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
2021
-
Impact of biological agents on postsurgical complications in inflammatory bowel disease: A multicentre study of geteccu
Journal of Clinical Medicine, Vol. 10, Núm. 19
-
Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study
Journal of Clinical Medicine, Vol. 10, Núm. 13
-
Risk and predictors of surgery in a newly diagnosed cohort of IBD patients in the biologic era: Results from the EpidemIBD study
Journal of Crohn's and Colitis, Vol. 15, Núm. Supplement_1, pp. S018-S020
2019
-
Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
Therapeutic Advances in Gastroenterology, Vol. 12
-
Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients
Digestive Diseases and Sciences, Vol. 64, Núm. 3, pp. 846-854
2018
2017
-
P186 Association between anti-TNF serum levels and mucosal healing in inflammatory bowel disease
Journal of Crohn's and Colitis, Vol. 11, Núm. suppl_1, pp. S171-S171
2016
-
Tuberculosis in anti-tumour necrosis factortreated inflammatory bowel disease patients after the implementation of preventive measures: Compliance with recommendations and safety of retreatment
Journal of Crohn's and Colitis, Vol. 10, Núm. 10
2015
-
Exome-wide pharmacogenomic analysis of response to thiopurines in inflammatory bowel disease patients
Current Pharmacogenomics and Personalized Medicine, Vol. 13, Núm. 1, pp. 61-67
2013
-
New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients
Pharmacogenomics, Vol. 14, Núm. 6, pp. 631-640
2012
-
Tu1909 An Exome-Wide Genotyping Analysis for the Identification of Candidate Genes Associated With the Response to the Thiopurine Therapy in Inflammatory Bowel Disease Patients
Gastroenterology, Vol. 142, Núm. 5, pp. S-875
2011
-
New Genetic Associations Detected in an Exome-Wide Association Study for Toxicity Related to Thiopurine Treatments in Inflammatory Bowel Disease
Gastroenterology, Vol. 140, Núm. 5, pp. S-271